Kaiju Biotechnology

Kaiju Biotechnology is an early-stage biopharmaceutical company focused on developing next-generation chimeric antigen receptor (CAR) T-cell therapies for solid tumors. The company aims to overcome the traditional barriers of the immunosuppressive tumor microenvironment that often limit the efficacy of cell therapies in non-liquid cancers. Their research primarily targets antigens such as GPC3 and Mesothelin, which are highly expressed in various solid malignancies including hepatocellular carcinoma. By leveraging advanced genetic engineering, Kaiju Biotechnology seeks to enhance the persistence and potency of engineered T-cells to provide durable clinical responses for patients with hard-to-treat cancers.